Synapse - David Hyman

Results (94)

Early phase I study of the PARP inhibitor veliparib (ART-888) alone or in combination with carboplatia/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG)

Meeting Abstract

Tawbi, H. A. H.; Chu, E.; Lin, Y.; Hyman, D. M.; Goel, S.; Rudek, M. A.; Dowlati, A.; LoRusso, P.; Mulkerin, D.; Chew, H. K.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in. colorectal cancer (CRC)

Meeting Abstract

Tabernero, J.; Chan, E.; Baselga, J.; Blay, J. Y.; Chau, I.; Hyman, D. M.; Raje, N. S.; Wolf, J.; Sirzén, F.; Veronese, M. L.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A phase 1 study of MEDI3617, a selective angiopoietin-2 inhibitor, alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizmab in patients with advanced solid tumors

Meeting Abstract

Hyman, D. M.; Rizvi, N. A.; Natale, R. B.; Armstrong, D. K.; Birrer, M. J.; Recht, L. D.; Dotan, E.; Gribbin, M. J.; McDevitt, J. T.; Tavakkoli, F.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m)

Meeting Abstract

Hyman, D. M.; Blay, J. Y.; Chau, I.; Raje, N. S.; Fernandez, M. E. E.; Wolf, J.; Sirzén, F.; Veronese, M. L.; Mitchell, L.; Puzanov, I.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Detection of BRAF mutations in urine and plasma cell-free DNA: Application to the diagnosis and management of histiocytic disorder patients

Meeting Abstract

Abdel-Wahab, O. I.; Diamond, E. L.; Patel, M.; Holley, V. R.; Cabrilo, G.; Rampal, R.; Hassaine, L.; Kosco, K.; Baselga, J.; Kurzrock, R.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Reply to M. Voskoboynik et al

Journal Article

Hyman, D. M.; Eaton, A. A.; Gounder, M. M.; Percy Ivy, S.; Iasonos, A.; Spriggs, D. R.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials

Journal Article

Hyman, D. M.; Eaton, A. A.; Gounder, M. M.; Smith, G. L.; Pamer, E. G.; Hensley, M. L.; Spriggs, D. R.; Ivy, P.; Iasonos, A.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience

Meeting Abstract

Grisham, R. N.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Iyer, G.; Hyman, D. M.; Spriggs, D. R.; Aghajanian, C.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

Detection of the NRAS Q61R mutation in Erdheim-Chester disease

Meeting Abstract

Diamond, E. L.; Pentsova, E.; Borsu, L.; Chiu, A. E.; Hyman, D. M.; Rosenblum, M.
Journal of Clinical Oncology (2013)

Fulltext@MSK | Save

BRCA1 immunohistochemistry in high-grade serous ovarian cancers (HGS-OC) characterized for BRCA1 germ-line mutations

Meeting Abstract

Hyman, D. M.; Garg, K.; Grisham, R. N.; Bhatia, J.; Arnold, A. G.; Aghajanian, C.; Kauff, N. D.; Levine, D. A.; Soslow, R. A.; Spriggs, D. R.
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save